(function(){var loadHandler=window['sl_{4D8E5DBA-A9FD-4AA9-B20B-4FE82EEC1058}'];loadHandler&&loadHandler(5, '<div id="spr0_317560"><div id="spr1_317560" class="kern slide"><img id="img0_317560" src="data/img1.png" width="960px" height="720px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_317560" class="kern slide"><div id="spr3_317560" style="left:48px;top:28.833px;"><div style="width:0px;"><span id="txt0_317560" data-width="420.070313" style="left:213.767px;top:0.375px;">OVERAL FRAMING</span></div></div><div id="spr4_317560" style="left:48px;top:97.315px;"><div style="width:0px;"><span id="txt1_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:0.612px;">•</span> <span id="txt2_317560" class="relpos" data-width="461.384125" style="left:35.33px;top:-4.007px;">Objective of economic evaluation</span> <span id="txt3_317560" class="relpos" data-width="280.614594" style="left:35.324px;top:-4.007px;">: to reduce the rate of</span></div><div style="width:0px;"><span id="txt4_317560" data-width="756.994812" style="left:45.6px;top:24.153px;">cardio- and cerebrovascular events and to increase Quality</span></div><div style="width:0px;"><span id="txt5_317560" data-width="348.677094" style="left:45.6px;top:52.313px;">Adjusted Life Years (QALY).</span></div><div style="width:0px;"><span id="txt6_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:91.634px;">•</span> <span id="txt7_317560" class="relpos" data-width="267.795593" style="left:35.33px;top:87.015px;">Relevant audience: </span> <span id="txt8_317560" class="relpos" data-width="225.929688" style="left:35.324px;top:87.015px;">health authorities</span></div><div style="width:0px;"><span id="txt9_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:126.834px;">•</span> <span id="txt10_317560" class="relpos" data-width="423.901062" style="left:35.33px;top:122.215px;">Time horizon and perspective: </span> <span id="txt11_317560" class="relpos" data-width="127.173180" style="left:35.324px;top:122.215px;">five years.</span></div><div style="width:0px;"><span id="txt12_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:162.034px;">•</span> <span id="txt13_317560" class="relpos" data-width="197.928391" style="left:35.33px;top:157.415px;">Target group: </span> <span id="txt14_317560" class="relpos" data-width="571.197937" style="left:35.324px;top:157.415px;">10 000 consecutive patients with DM type 2,</span></div><div style="width:0px;"><span id="txt15_317560" data-width="784.007813" style="left:45.6px;top:186.073px;">equal gender, on single therapy with well-controlled disease,</span></div><div style="width:0px;"><span id="txt16_317560" class="relpos" data-width="207.940109" style="left:45.6px;top:214.233px;">above 40 years. </span> <span id="txt17_317560" class="relpos" data-width="261.746735" style="left:45.593px;top:214.233px;">Exclusion criteria: </span> <span id="txt18_317560" class="relpos" data-width="260.619812" style="left:45.587px;top:214.233px;">patients with known</span></div><div style="width:0px;"><span id="txt19_317560" data-width="802.613281" style="left:45.6px;top:242.393px;">coronary artery disease (CAD), peripheral artery disease (PAD),</span></div><div style="width:0px;"><span id="txt20_317560" class="relpos" data-width="607.019531" style="left:45.6px;top:270.553px;">cancer, heart, liver and kidney failure patients), </span> <span id="txt21_317560" class="relpos" data-width="205.973282" style="left:45.593px;top:270.553px;">distribution in</span></div><div style="width:0px;"><span id="txt22_317560" class="relpos" data-width="136.607407" style="left:45.6px;top:298.713px;">2 groups </span> <span id="txt23_317560" class="relpos" data-width="350.324219" style="left:45.593px;top:298.713px;">(Metformin vs dulaglutide).</span></div><div style="width:0px;"><span id="txt24_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:338.034px;">•</span> <span id="txt25_317560" class="relpos" data-width="414.218750" style="left:35.33px;top:333.415px;">Type of economic evaluation: </span> <span id="txt26_317560" class="relpos" data-width="333.924500" style="left:35.324px;top:333.415px;">Cost-efectiveness analysis</span></div><div style="width:0px;"><span id="txt27_317560" class="relpos" style="left:45.6px;top:362.073px;">(</span> <span id="txt28_317560" class="relpos" data-width="409.119812" style="left:45.593px;top:362.073px;">CEA), cost-utility analysis (CUA).</span></div><div style="width:0px;"><span id="txt29_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:401.394px;">•</span> <span id="txt30_317560" class="relpos" data-width="680.625000" style="left:35.33px;top:396.775px;">Definition of incremental cost effectiveness ratio:</span></div><div style="width:0px;"><span id="txt31_317560" data-width="625.653687" style="left:45.6px;top:425.433px;">differences in costs divided in costs of outcomes</span></div><div style="width:0px;"><span id="txt32_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:464.754px;">•</span> <span id="txt33_317560" class="relpos" data-width="420.606781" style="left:35.33px;top:460.135px;">Country and centers included: </span> <span id="txt34_317560" class="relpos" data-width="269.227875" style="left:35.324px;top:460.135px;">Manchester NHS, UK</span></div><div style="width:0px;"><span id="txt35_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:499.954px;">•</span> <span id="txt36_317560" class="relpos" data-width="102.595055" style="left:35.33px;top:495.335px;">Design:</span> <span id="txt37_317560" class="relpos" data-width="267.566406" style="left:35.324px;top:495.335px;"> double-blinded RCT</span></div><div style="width:0px;"><span id="txt38_317560" class="nokern relpos" dir="auto" style="left:9.6px;top:535.154px;">•</span> <span id="txt39_317560" class="relpos" data-width="393.794281" style="left:35.33px;top:530.535px;">Data sources and collection: </span> <span id="txt40_317560" class="relpos" data-width="65.369797" style="left:35.324px;top:530.535px;">eCFR</span></div></div></div></div>', '{"s":[]}');})();